Generation of a predictive melphalan resistance index by drug screen of b-cell cancer cell lines

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Boegsted, Martin ^a   Holst, Johanne M ^a   Fogd, Kirsten ^a   Falgreen, Steffen ^a   Sørensen, Suzette ^a   Schmitz, Alexander ^a   Bukh, Anne ^a   Johnsen, Hans E ^a   Nyegaard, Mette ^a   Dybkaer, Karen ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SCREENING; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; INTERNAL VALIDITY; LARGE CELL LYMPHOMA; MELPHALAN RESISTANCE INDEX; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; PLASMACYTOMA; PREDICTION; PREDICTIVE VALUE; RECURRENCE RISK; B LYMPHOCYTE; DNA MICROARRAY; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; METHODOLOGY; REGRESSION ANALYSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEAST-SQUARES ANALYSIS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MELPHALAN; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMACYTOMA;

EID: 79955778237     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019322     Document Type: Article

References (41)

1. Samuels BL, Bitran JD, (1995) High-dose intravenous melphalan: a review. J Clin Oncol 13: 1786-1799.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, et al. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348: 1875-1883.
3. Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, et al. (2009) Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res 69: 9367-9375.
4. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244.
5. Coombes KR, Wang J, Baggerly KA, (2007) Microarrays: retracing steps. Nat Med 13: 1276-1277.
6. Baggerly KA, Coombes KR, (2009) Deriving chemosensitivity from cell lines: forensic bioinformatics and reproducible research in high-throughput biology. Ann Appl Stat 3: 1309-1334.
7. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, et al. (2007) A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 104: 13086-13091.
8. Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, et al. (2010) Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat 121: 301-309.
9. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, et al. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354: 1021-1030.
10. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, et al. (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766.
11. Shoemaker RH, (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
12. Boyd MR, Paull KD, (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res 34: 91-109.
13. Goldman-Leikin RE, Salwen HR, Herst CV, Variakojis D, Bian ML, et al. (1989) Characterization of a novel myeloma cell line, MM.1. J Lab Clin Med 113: 335-345.
14. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM, (1991) Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 51: 995-1002.
15. Mehra S, Messner H, Minden M, Chaganti RSK, (2002) Molecular cytogenetic characterization of non-Hodgkin lymphoma cell lines. Gene Chromosomes Cancer 33: 225-234.
16. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, et al. (2006) The molecular classification of multiple myeloma. Blood 108: 2020-2028.
17. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, et al. (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354: 2419-2430.
18. Leisch F, Rossini AJ, (2003) Reproducible statistical research. Chance 16: 46-50.
19. The R Development Core Team (2010) R: A language and environment for statistical computing Austria R Foundation for Statistical Computing Vienna ISBN 3-900051-07-0. http://www.R-project.org/.
20. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80.
21. Grubbs FE, (1950) Sample criteria for testing outlying observations. Ann Math Statist 21: 27-58.
22. Havaleshko DM, Cho H, Conaway M, Owens CR, Hampton G, et al. (2007) Prediction of drug combination chemosensitivity in human bladder cancer. Mol Cancer Ther 6: 578-586.
23. Kauffmann A, Gentleman R, Huber W, (2009) arrayQualityMetrics-a bioconductor package for quality assessment of microarray data. Bioinformatics 25: 415-416.
24. Smyth GK, (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
25. Ahdesmäki M, Strimmer K, (2010) Feature selection in omics prediction problems using cat scores and false nondiscovery rate control. Ann Appl Stat 4: 503-519.
26. Chun H, Keleş S, (2010) Sparse partial least squares regression for simultaneous dimension reduction and variable selection. J R Stat Soc Series B Stat Methodol 72: 3-25.
27. Subramanian J, Simon R, (2010) What should physicians look for in evaluating prognostic gene-expression signatures? Nat Rev Clin Oncol 7: 327-334.
28. Bourgon R, Gentleman R, Huber W, (2010) Independent filtering increases detection power for high-throughput experiments. Proc Natl Acad Sci U S A 107: 9546-9551.
29. Harrell FE, (2001) Regression Modeling Strategies New York Springer Verlag.
30. Chen Q, Van Der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS, (2005) The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 106: 698-705.
31. Shen C, Ye Y, Robertson SE, Lau AW, Mak DO, et al. (2005) Calcium/calmodulin regulates ubiquitination of the ubiquitin-specific protease TRE17/USP6. J Biol Chem 280: 35967-35973.
32. Tan Y, Sangfelt O, Spruck C, (2008) The Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett 271: 1-12.
33. Burr ML, Cano F, Svobodova S, Boyle LH, Boname JM, et al. (2011) HRD1 and UBE2J1 target misfolded MHC class I heavy chains for endoplasmic reticulum-associated degradation. Proc Natl Acad Sci U S A 108: 2034-2039.
34. Messick TE, Greenberg RA, (2009) The ubiquitin landscape at DNA double-strand breaks. J Cell Biol 187: 319-326.
35. Kimura T, Gotoh M, Nakamura Y, Arakawa H, (2003) hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci 94: 431-436.
36. Topol L, Jiang X, Choi H, Garrett-Beal L, Carolan PJ, et al. (2003) Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J Cell Biol 162: 899-908.
37. Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, et al. (2009) Aurora kinase is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood 114: 2699-2708.
38. Bret C, Hose D, Reme T, Sprynski AC, Mahtouk K, et al. (2009) Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells. Br J Haematol 145: 350-368.
39. Sato T, Gotoh M, Kiyohara K, Akashima T, Iwasaki H, et al. (2003) Differential roles of two N-acetylgalactosaminyltransferases, CSGalNAcT-1, and a novel enzyme, CSGalNAcT-2. Initiation and elongation in synthesis of chondroitin sulfate. J Biol Chem 278: 3063-3071.
40. Rapraeger A, Jalkanen M, Endo E, Koda J, Bernfield M, (1985) The cell surface proteoglycan from mouse mammary epithelial cells bears chondroitin sulfate and heparan sulfate glycosaminoglycans. J Biol Chem 260: 11046-11052.
41. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, et al. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J of Haematol 102: 1115-11123.